ATE425251T1 - Impfstoffe welche antiidiotypische antikörper enthalten, die kohlenhydrate von streptococcus gruppe b nachahmen - Google Patents

Impfstoffe welche antiidiotypische antikörper enthalten, die kohlenhydrate von streptococcus gruppe b nachahmen

Info

Publication number
ATE425251T1
ATE425251T1 AT99914725T AT99914725T ATE425251T1 AT E425251 T1 ATE425251 T1 AT E425251T1 AT 99914725 T AT99914725 T AT 99914725T AT 99914725 T AT99914725 T AT 99914725T AT E425251 T1 ATE425251 T1 AT E425251T1
Authority
AT
Austria
Prior art keywords
mimic
carbohydrates
vaccines containing
streptococcus group
antidiotypic
Prior art date
Application number
AT99914725T
Other languages
English (en)
Inventor
Giuseppe Teti
Luciano Polonelli
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE425251T1 publication Critical patent/ATE425251T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4233—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-bacterial Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99914725T 1998-04-20 1999-04-20 Impfstoffe welche antiidiotypische antikörper enthalten, die kohlenhydrate von streptococcus gruppe b nachahmen ATE425251T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9808327.2A GB9808327D0 (en) 1998-04-20 1998-04-20 Antidiotypic compounds

Publications (1)

Publication Number Publication Date
ATE425251T1 true ATE425251T1 (de) 2009-03-15

Family

ID=10830608

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99914725T ATE425251T1 (de) 1998-04-20 1999-04-20 Impfstoffe welche antiidiotypische antikörper enthalten, die kohlenhydrate von streptococcus gruppe b nachahmen

Country Status (9)

Country Link
US (2) US6676938B1 (de)
EP (1) EP1071763B1 (de)
JP (2) JP4446601B2 (de)
AT (1) ATE425251T1 (de)
CA (1) CA2325566C (de)
CY (1) CY1109140T1 (de)
DE (1) DE69940545D1 (de)
GB (1) GB9808327D0 (de)
WO (1) WO1999054457A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027695A1 (de) * 1999-05-27 2001-04-19 Max Delbrueck Centrum Vakzine gegen konformationsabhängige Antigene sowie gegen Antigene, die keine oder nicht ausschließlich Proteine oder Peptide sind
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
WO2004018646A2 (en) * 2002-08-26 2004-03-04 Chiron Corporation Conserved and specific streptococcal genomes
PT1648500E (pt) 2003-07-31 2014-10-10 Novartis Vaccines & Diagnostic Composições imunogénicas para estreptococos piogenes
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
US20090317420A1 (en) * 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
US7838010B2 (en) * 2004-10-08 2010-11-23 Novartis Vaccines And Diagnostics S.R.L. Immunogenic and therapeutic compositions for Streptococcus pyogenes
AU2005319174A1 (en) * 2004-12-22 2006-06-29 J. Craig Venter Institute, Inc. Group B Streptococcus
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
DK2054431T3 (da) * 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
EP2586790A3 (de) 2006-08-16 2013-08-14 Novartis AG Immunogene von uropathogenen Escherichia coli
CA2668018A1 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
US8287885B2 (en) 2007-09-12 2012-10-16 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
AU2008339551B2 (en) 2007-12-21 2013-10-24 Glaxosmithkline Biologicals S.A. Mutant forms of streptolysin O
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
EP2834259A4 (de) 2012-04-02 2016-08-24 Moderna Therapeutics Inc Modifizierte polynukleotide
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (de) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynukleotide zur codierung von low-density-lipoprotein-rezeptor
US11278427B2 (en) 2018-04-10 2022-03-22 Gary A. Zick, Trustee Of The Everest Trust Uta April 20, 2017 Spinal interbody cage comprising top and bottom faces with mesh structures, pillars and slots

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476784A (en) * 1993-04-06 1995-12-19 Rice; Peter A. Gonococcal anti-idiotypic antibodies and methods and compositions using them
EP1015489B1 (de) * 1996-05-29 2006-07-05 Derek Nigel John Hart Rezeptor von dendritischen zellen.
US6140091A (en) * 1997-06-20 2000-10-31 Boston Biomedical Research Institute Anti-idiotype vaccines to elicit catalytic antibodies
US6444787B1 (en) * 1997-12-31 2002-09-03 Research Development Institute, Inc. Method of isolating a peptide which immunologically mimics microbial carbohydrates including group B streptococcal carbohydrates and the use thereof in a vaccine

Also Published As

Publication number Publication date
CY1109140T1 (el) 2014-07-02
JP2009179645A (ja) 2009-08-13
DE69940545D1 (de) 2009-04-23
EP1071763A1 (de) 2001-01-31
CA2325566A1 (en) 1999-10-28
US6900302B2 (en) 2005-05-31
US6676938B1 (en) 2004-01-13
WO1999054457A1 (en) 1999-10-28
JP4446601B2 (ja) 2010-04-07
EP1071763B1 (de) 2009-03-11
US20040101536A1 (en) 2004-05-27
JP2002512026A (ja) 2002-04-23
GB9808327D0 (en) 1998-06-17
CA2325566C (en) 2011-02-08

Similar Documents

Publication Publication Date Title
ATE425251T1 (de) Impfstoffe welche antiidiotypische antikörper enthalten, die kohlenhydrate von streptococcus gruppe b nachahmen
DK0673255T3 (da) Monoklonale antistoffer, som specifikt binder til vaskulært tumorendotel, og anvendelser deraf
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
YU48509B (sh) Suspenzije u kondenzovanim potisnim gasovima
FI882173A7 (fi) Synteettinen peptidiantigeeni HIV-2-tartunnan toteamiseksi.
DK234789D0 (da) Antistoffer mod latente human papillomavirusproteiner, diagnostiske systemer og diagnostiske metoder
BR9407377A (pt) Toxina hibrida
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
FI953442A0 (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
EA200100565A1 (ru) Новые стрептококковые антигены
IT8819187A0 (it) Sistema di bilanciamento mediante pistone a vapore in trazione, particolarmente per turbomotori agas.
TR199801722T2 (xx) Peptit imm�nojenler.
DE69636453D1 (de) Modulation der aktivität des cholesteryl-ester-transfer-proteins (cetp)
ATE444360T1 (de) T-zell epitopen von den wichtigsten allergene von dermatophagoides (hausmilbe)
HUP9902457A2 (hu) Pneumococcus felületi fehérjéket tartalmazó oltóanyag-készítmények
NO910656D0 (no) Sperrevaeske-tetningsanordning for turbokompressor.
ATE197506T1 (de) Breitreaktive opsonische antikörper die mit gemeinsamen antigenen von staphylococcus reagieren
WO1998039450A3 (de) Oberflächenprotein (spsa-protein) von streptococcus pneumoniae deletierte abkömmlinge, expressionssssystem für diese proteine und vaccine mit den proteinen
DE68917556D1 (de) Quinolyloxazol-2-one, nützlich als Proteinkinase-C-Inhibitoren.
DE3382718D1 (de) Peptide, die eine Immunogen-Lage des Poliovirus des Sabin-Stammes enthalten.
NO910655D0 (no) Sperrevaeske-tetningsanordning for turbokompressor.
FI911973A0 (fi) Traodaktigt hemagglutinin av b. pertussis-bacill.
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
ATE120209T1 (de) Isolierung von einkettigen proteinen mit fsh unter- drückender aktivität aus follikularflüssigkeit.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1071763

Country of ref document: EP